Published

Expert recommendations for Germany's integration of psychedelic-assisted therapy.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: BMC medical education
Date: 2024-10-24
Source: PubMed
DOI: 10.1186/s12909-024-06141-3
PubMed: 39443907

Authors

Perez Rosal SR La Torre JT Birnkammer S Chernoloz O Williams MT Faber SC

Watch author

Derived topics and classifications

psilocybin PTSD Mechanism of Action Clinical Trial Clinical Trial

Citation graph

0 referenced DOIs found in stored source metadata. 4 indexed papers cite this DOI.

Open citation network

Indexed papers citing this DOI

Quantifying psilocybin exposure in a natural product-based retreat setting: An observational field method for dose measurement2026-12-01 Bridging the reporting gap: Application of the ReSPCT guidelines in psilocybin clinical trial protocols2026-04-01 Psilocybin in Neuropsychiatric Disorders: Seeking Valuable Evidence in History, Pure Science, Clinical Trials and Real-World Data (RWD)2026-03-26 Expert recommendations for Germany's integration of psychedelic-assisted therapy.2024-10-24

Related papers

Psychedelics and mental health: reimagining care through science, insight, and compassion.Frontiers in pharmacology · 2025-01-01 Investigation of Psychedelic Effects in Psychoactive SubstancesClinicalTrials.gov · 2026-02-23 Psilocybin and MDMA for Post-traumatic Stress Disorder (PTSD)ClinicalTrials.gov · 2025-10-01 The Role of Personal Experience for the Therapeutic Attitude in the Context of Substance-assisted Therapy TrainingClinicalTrials.gov · 2025-04-14